12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tasimelteon: Phase III started

Vanda began the double-blind, placebo-controlled, U.S. Phase III trial (Study 3201) to evaluate 20 mg tasimelteon given daily for 6 months in about 160 totally blind patients. Vanda...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >